|1.||Kloppenburg, Geoffrey: 2 articles (03/2009 - 01/2009)|
|2.||Stassen, Frank: 2 articles (03/2009 - 01/2009)|
|3.||de Graaf, Rick: 2 articles (03/2009 - 01/2009)|
|4.||Schrepfer, Sonja: 2 articles (01/2007 - 01/2007)|
|5.||Schäfer, Hansjörg: 2 articles (01/2007 - 01/2007)|
|6.||Deuse, Tobias: 2 articles (01/2007 - 01/2007)|
|7.||Robbins, Robert C: 2 articles (01/2007 - 01/2007)|
|8.||Haddad, Munif: 2 articles (01/2007 - 01/2007)|
|9.||Pelletier, Marc P: 2 articles (01/2007 - 01/2007)|
|10.||Reichenspurner, Hermann: 2 articles (01/2007 - 01/2007)|
01/15/2005 - "Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats."
07/01/2007 - "The association of tacrolimus and FK778 from day 1, compared to the delayed administration of FK778 from day 7, results in a significant reduction of infections and postoperative complications."
01/01/2005 - "Treatment of HCMV-infected cells with FK778 prevented the appearance of HCMV proteins some 12-24h post infection, and inhibited viral DNA synthesis. "
01/01/2007 - "To investigate the efficacy of the malononitrilamide FK778 to prevent vascular smooth muscle cell (SMC) migration/proliferation, and vascular fibrosis, the key events in restenosis development using in vivo and in vitro studies. "
01/01/2007 - "The malononitrilamide FK778 proved highly efficacious against restenosis development by targeting two major components of intimal hyperplasia: SMC proliferation/migration and vascular fibrosis. "
07/01/2005 - "In both dose groups, there was a trend toward inhibition of neointima formation when the 5-day course of FK778 was started before or 1 day after the intervention. "
08/15/2003 - "Our results demonstrate that FK778 inhibits neointima formation by way of a mechanism that is independent of DHODH inhibitory activity on vascular smooth muscle cell. "
03/01/2009 - "We show that the immunosuppressive agent FK778 can prevent neointima formation in experimental venous bypass grafts by inhibiting venous SMC proliferation. "
03/01/2009 - "The effect of FK778 treatment on neointima formation in vivo was assessed in an autologous epigastric vein-to femoral artery interposition graft model in rats. "
03/01/2009 - "We examined the inhibitory potential of FK778 on venous SMC proliferation and neointima formation in an experimental venous bypass graft model. "
01/01/2009 - "Furthermore, we evaluated the potential of FK778 to prevent intimal hyperplasia. "
01/01/2009 - "Also, our results suggest a prospective role for the new immunosuppressive drug FK778 in the prevention of (CMV-mediated) vein graft intimal hyperplasia."
01/01/2009 - "Apart from its antiviral properties, FK778 is a new immunosuppressive agent which may also affect SMC proliferation, making it an interesting drug to prevent (CMV-enhanced) venous graft intimal hyperplasia. "
01/01/2009 - "FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model."
07/01/2005 - "With the higher dose, suppression of intimal hyperplasia was significant when FK778 was administered between days 1 and 5 after angioplasty (group 2b; P<.01). "
01/01/2010 - "At week 16, rats with I/R injury and FK778 treatment had lower proteinuria compared with placebo-treated rats (I/R 3 mg: 48.42 +/- 26.16, I/R 10 mg 27.28 +/- 21.86 vs. Placebo: 70.13 +/- 50.19 mg/day, P < 0.05). "
03/27/2007 - "Continuous treatment with FK778 ameliorated the progression of CAN, whereas late treatment reduced proteinuria and resulted in a similar grade of CAN as compared to animals with continuous treatment. "
04/27/2003 - "Recipients treated with FK778 for 10 days exhibited a dose-dependent decrease in proteinuria and plasma creatinine for the entire 90-day period after transplantation when compared with the allograft control. "
|6.||Immunosuppressive Agents (Immunosuppressants)
|8.||Proteins (Proteins, Gene)
|10.||glucuronyl glucosamine glycan sulfate (Vessel)
|2.||Heart Transplantation (Grafting, Heart)
|4.||Homologous Transplantation (Allograft)
|5.||Angioplasty (Angioplasty, Transluminal)